Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1458 results found since Jan 2013.
C.D.C. Recommends New Covid Vaccines for All Americans
Everyone aged 6 months and older should get at least one dose, the agency said.
Source: NYT Health - September 12, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Drugs (Pharmaceuticals) Vaccination and Immunization Coronavirus (2019-nCoV) Influenza Centers for Disease Control and Prevention Moderna Inc Pfizer Inc Source Type: news
C.D.C. Advisers Recommend New Covid Vaccines for All Americans
Everyone aged 6 months and older should get at least one dose, the panel said.
Source: NYT Health - September 12, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Drugs (Pharmaceuticals) Vaccination and Immunization Coronavirus (2019-nCoV) Influenza Centers for Disease Control and Prevention Moderna Inc Pfizer Inc Source Type: news
C.D.C. Advisers to Decide Who Should Receive New Covid Vaccines
Scientists will meet on Tuesday to consider data on newly approved shots from Pfizer and Moderna.
Source: NYT Health - September 12, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Drugs (Pharmaceuticals) Vaccination and Immunization Coronavirus (2019-nCoV) Influenza Centers for Disease Control and Prevention Moderna Inc Pfizer Inc Source Type: news
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
ConclusionsBNT162b2 coadministered with SIIV elicited immune responses that were noninferior to those elicited by BNT162b2 alone and SIIV alone, and BNT162b2 had an acceptable safety profile when coadministered with SIIV. The results of this study support the coadministration of BNT162b2 and SIIV in adults.Trial RegistrationClinicalTrials.gov registration: NCT05310084.
Source: Infectious Diseases and Therapy - September 12, 2023 Category: Infectious Diseases Source Type: research
F.D.A. Approves New Covid Shots
A nationwide rollout of the vaccines by Pfizer and Moderna should begin later this week, after the C.D.C. considers guidelines to prepare Americans for this season when infections usually tick upward.
Source: NYT Health - September 11, 2023 Category: Consumer Health News Authors: Christina Jewett and Noah Weiland Tags: Drugs (Pharmaceuticals) Vaccination and Immunization Coronavirus (2019-nCoV) Deaths (Fatalities) Influenza Elderly Health Insurance and Managed Care Respiratory Syncytial Virus (RSV) Coronavirus Omicron Variant Immune System BioNTech S Source Type: news
Covid Vaccines May Roll Out Within Days
The F.D.A. is expected to approve a new round of shots by Pfizer and Moderna as early as Monday to prepare Americans for the fall and winter season when infections usually tick upward.
Source: NYT Health - September 11, 2023 Category: Consumer Health News Authors: Christina Jewett Tags: Drugs (Pharmaceuticals) Vaccination and Immunization Coronavirus (2019-nCoV) Deaths (Fatalities) Influenza Elderly Health Insurance and Managed Care Respiratory Syncytial Virus (RSV) Coronavirus Omicron Variant Immune System BioNTech S Source Type: news
Should I get a COVID-19 booster?
On 12 September, a vaccine advisory group to the Centers for Disease Control and Prevention (CDC) once again will wrestle with the question of who in the United States should receive a booster shot to protect against COVID-19.
As several new variants and an uptick in COVID-19 hospitalization fuel concerns among some health officials and the public, three companies have made new COVID-19 vaccines that can be used as a booster (or as primary doses for the unvaccinated). The Food and Drug Administration (FDA) is expected to approve at least one of these latest iterations before Tuesday’s meeting of CDC’s Advisory Com...
Source: Science of Aging Knowledge Environment - September 8, 2023 Category: Geriatrics Source Type: research
Comprehensive care of adults with respiratory diseases must include vaccines
Vaccines are among the most effective tools we have to improve and save lives, but only if they are administered to eligible patients. In this issue, Naeger et al1 highlight the major opportunities that the health care community has to achieve high adult vaccination rates. These vaccines include those for prevention of coronavirus disease 2019 (COVID-19), pneumococcal, and influenza, diseases that respiratory health professionals are most aware of, plus pertussis (in Tdap), herpes zoster (HZ, shingles), and as of May 3, 2023, respiratory syncytial viral, for which adults with asthma and chronic obstructive pulmonary diseas...
Source: Annals of Allergy, Asthma and Immunology - September 1, 2023 Category: Allergy & Immunology Authors: Barbara P. Yawn, Dennis Williams, Gregory Poland Tags: Editorial Source Type: research
The Next Generation COVID ‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2
The solubility challenge of niclosamide is resolved with an exclusive drug delivery technology using biocompatible inorganic MgO and hydroxypropyl methylcellulose polymer that has enhanced the solubility and intestinal absorption, thereby prolonged and sustained release of niclosamide, eventually improving the antiviral effect in the lungs without causing any adverse effects according to the preclinical and clinical studies. AbstractThe coronavirus disease 2019 (COVID-19) pandemic is a serious global threat with surging new variants of concern. Although global vaccinations have slowed the pandemic, their longevity is still...
Source: Small - August 28, 2023 Category: Nanotechnology Authors: Goeun Choi,
N. Sanoj Rejinold,
Huiyan Piao,
Young Bae Ryu,
Hyung ‐Jun Kwon,
In Chul Lee,
Jeong In Seo,
Hye Hyun Yoo,
Geun‐woo Jin,
Jin‐Ho Choy Tags: Research Article Source Type: research
Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study
CONCLUSIONS: A sizeable proportion of older adults who received other recommended vaccines during the last influenza season did not receive SIV. This share of missed opportunities, which are subject to some social inequalities, may be addressed by increasing vaccine co-administration rates and implementing tailored health promotion interventions.PMID:37632235 | DOI:10.1093/eurpub/ckad155
Source: Herpes - August 26, 2023 Category: Infectious Diseases Authors: Alexander Domnich Andrea Orsi Matilde Ogliastro Carlo-Simone Trombetta Marianna Scarpaleggia Chiara Ceccaroli Carla Amadio Anna Raffo Luca Berisso Alla Yakubovich Giacomo Zappa Daniela Amicizia Donatella Panatto Giancarlo Icardi Source Type: research
Age-specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands
CONCLUSION: Whereas the increase in severity of Severe Acute Respiratory Syndrome Coronavirus 2 with age remained stable, the risk of death upon infection decreased over time. A significant drop in risk of death among elderly coincided with the introduction of COVID-19 vaccination.PMID:37621921 | PMC:PMC10444602 | DOI:10.1111/irv.13174
Source: Respiratory Care - August 25, 2023 Category: Respiratory Medicine Authors: Pieter T de Boer Jan van de Kassteele Eric R A Vos Liselotte van Asten Dave A Dongelmans Arianne B van Gageldonk-Lafeber Gerco den Hartog Agnetha Hofhuis Fiona van der Klis Dylan W de Lange Lenny Stoeldraijer RIVM COVID ‐19 epidemiology and surveillance Source Type: research
Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus
Bacteria are well known to provide heterologous immunity against viral infections through various mechanisms including the induction of innate trained immunity and adaptive cross-reactive immunity. Cross-reactive immunity from bacteria to viruses is responsible for long-term protection and yet its role has been downplayed due the difficulty of determining antigen-specific responses. Here, we carried out a systematic evaluation of the potential cross-reactive immunity from selected bacteria known to induce heterologous immunity against various viruses causing recurrent respiratory infections. The bacteria selected in this w...
Source: Frontiers in Immunology - August 22, 2023 Category: Allergy & Immunology Source Type: research
